Segantii Capital Management’s Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant BACA.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-100,000
Closed -$986K 671
2021
Q3
$986K Buy
+100,000
New +$985K 0.03% 194

Other funds holding BACA.U

Segantii Capital Management's BACA.U Position: Q4 2021 in Review

Segantii Capital Management sold out of Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant (BACA.U) in Q4 2021, closing a stake of 100,000 shares — an estimated $986K sold.

Segantii Capital Management first reported a position in BACA.U in Q3 2021 and held it in 1 quarter. The position peaked at $986K in Q3 2021. 24 funds tracked by Wall St. Rank hold BACA.U as of Q4 2021.

  • Segantii Capital Management reported no remaining Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant position as of Q4 2021 after selling out during the quarter.
  • Segantii Capital Management sold 100,000 Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant shares in Q4 2021, an estimated $986K.
  • Segantii Capital Management first reported a position in Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant in Q3 2021 and held it in 1 quarter.
  • Segantii Capital Management's Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant position peaked at $986K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Berenson Acquisition Corp. I Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant as of Q4 2021.

Based on Segantii Capital Management's 13F filing for Q4 2021, filed 21 Jan 2022.